Citadel Advisors
SABS icon

Citadel Advisors’s SAB Biotherapeutics SABS Stock Holding History

Citadel Advisors’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,700
Closed -$102K – 14694
2026
Q1 		$102K Buy
+26,700
New +$106K ﹤0.01% 12003

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors's SABS Position: Q2 2026 in Review

Citadel Advisors opened a new position in SAB Biotherapeutics (SABS) in Q2 2026: 62,797 shares worth $245K. The stake represents ﹤0.01% of the portfolio and ranks #11587 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in SABS as recently as Q4 2025.

Citadel Advisors first reported a position in SABS in Q1 2021 and has held it in 12 quarters since. The position peaked at $452K in Q1 2021. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Citadel Advisors held 62,797 shares of SAB Biotherapeutics worth $245K as of Q2 2026.
  • SAB Biotherapeutics was a new Citadel Advisors position in Q2 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11587 holding.
  • Citadel Advisors first reported a position in SAB Biotherapeutics in Q1 2021 and has held it in 12 quarters since.
  • Citadel Advisors's SAB Biotherapeutics position peaked at $452K in Q1 2021.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.